Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2018 Filed Sep 5, 2018 20:15 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 5,000 | $36.02 | $180,100.00 |
DisclosureSEC source: 0001225208-18-013152 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 20:15 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionCommon Stock | 5,000 | $7.16 | $35,800.00 |
DisclosureSEC source: 0001225208-18-013152 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 12:28 UTC |
Sununu John EDirector
|
SaleCommon Stock | 72 | $34.87 | $2,510.64 |
DisclosureSEC source: 0001225208-18-012656 · doc4.xml · nonDerivative · entry 1 Sununu John E · CIK 0001458974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,265 Read SEC document |
| August 13, 2018 Filed Jan 3, 2019 21:55 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
GiftCommon Stock | 1,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000436 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,308 Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 20:21 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-012188 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,640 Underlying: Common Stock · 5,000 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 20:21 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 5,000 | $33.66 | $168,322.50 |
DisclosureSEC source: 0001225208-18-012188 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $33.6601 to $33.67, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 20:21 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionCommon Stock | 5,000 | $7.16 | $35,800.00 |
DisclosureSEC source: 0001225208-18-012188 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 20:25 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 33,512 | $0.00 Strike: $8.30 | $0.00 |
DisclosureSEC source: 0001225208-18-011604 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,512 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2010, the first anniversary of the date of grant. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 20:25 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
SaleCommon Stock | 33,512 | $34.00 | $1,139,414.70 |
DisclosureSEC source: 0001225208-18-011604 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,162 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $34.00 and $34.01. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 20:25 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 33,512 | $8.30 | $278,149.60 |
DisclosureSEC source: 0001225208-18-011604 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| July 02, 2018 Filed Jul 2, 2018 20:29 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-011027 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,640 Underlying: Common Stock · 5,000 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| July 02, 2018 Filed Jul 2, 2018 20:29 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 5,000 | $32.42 | $162,118.50 |
DisclosureSEC source: 0001225208-18-011027 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| July 02, 2018 Filed Jul 2, 2018 20:29 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionCommon Stock | 5,000 | $7.16 | $35,800.00 |
DisclosureSEC source: 0001225208-18-011027 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:14 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
SaleCommon Stock | 19,323 | $32.64 | $630,702.72 |
DisclosureSEC source: 0001225208-18-010732 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,162 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 20:17 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 37,430 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-18-010615 · doc4.xml · derivative · entry 7 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,430 Underlying: Common Stock · 37,430 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 20:17 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 31,056 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-010615 · doc4.xml · derivative · entry 6 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,056 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 20:17 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
SaleCommon Stock | 36,730 | $35.87 | $1,317,512.45 |
DisclosureSEC source: 0001225208-18-010615 · doc4.xml · nonDerivative · entry 5 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,151 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.63 to $36.445, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 20:17 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
SaleCommon Stock | 31,056 | $32.00 | $993,792.00 |
DisclosureSEC source: 0001225208-18-010615 · doc4.xml · nonDerivative · entry 4 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,881 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 20:17 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
SaleCommon Stock | 700 | $36.77 | $25,739.00 |
DisclosureSEC source: 0001225208-18-010615 · doc4.xml · nonDerivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,937 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 20:17 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionCommon Stock | 31,056 | $7.16 | $222,360.96 |
DisclosureSEC source: 0001225208-18-010615 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 20:17 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionCommon Stock | 37,430 | $7.39 | $276,607.70 |
DisclosureSEC source: 0001225208-18-010615 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 20:15 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 1,650 | $30.83 | $50,874.62 |
DisclosureSEC source: 0001225208-18-010483 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $30.8301 and $30.835. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:08 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-010105 · doc4.xml · derivative · entry 6 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,640 Underlying: Common Stock · 5,000 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase 77,640 shares of common stock vesting in four annual increments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:08 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionDeferred Stock Units · Derivative | 2,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-010105 · doc4.xml · derivative · entry 5 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,917 Underlying: Common Stock · 2,972 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:08 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 5,000 | $30.58 | $152,914.00 |
DisclosureSEC source: 0001225208-18-010105 · doc4.xml · nonDerivative · entry 4 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,851 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:08 UTC |
Pierce David AEVP,Pres MedSurg
|
Tax withholdingCommon Stock | 1,322 | $30.59 | $40,439.98 |
DisclosureSEC source: 0001225208-18-010105 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,851 Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:08 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionCommon Stock | 2,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-010105 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:08 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionCommon Stock | 5,000 | $7.16 | $35,800.00 |
DisclosureSEC source: 0001225208-18-010105 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:08 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionDeferred Stock Units · Derivative | 1,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-010106 · doc4.xml · derivative · entry 4 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,284 Underlying: Common Stock · 1,761 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:08 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Tax withholdingCommon Stock | 829 | $30.59 | $25,359.11 |
DisclosureSEC source: 0001225208-18-010106 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,416 Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:08 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionCommon Stock | 1,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-010106 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:08 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
SaleCommon Stock | 20,015 | $30.15 | $603,368.19 |
DisclosureSEC source: 0001225208-18-009556 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,858.99 F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $30.14 to $30.155, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:43 UTC |
FUJIMORI YOSHIAKIDirector
|
GrantDeferred Stock Units · Derivative | 6,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009207 · doc4.xml · derivative · entry 1 FUJIMORI YOSHIAKI · CIK 0001233160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,121 Underlying: Common Stock · 6,109 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:43 UTC |
MACMILLAN STEPHEN PDirector
|
GrantDeferred Stock Units · Derivative | 3,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009208 · doc4.xml · derivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,602 Underlying: Common Stock · 3,797 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: Reflects a value of $115,000 divided by the closing price of common stock on the date of grant. F5 · derivative.exercise_date: Deferred stock units were granted in lieu of quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F5 · derivative.expiration_date: Deferred stock units were granted in lieu of quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:43 UTC |
MACMILLAN STEPHEN PDirector
|
GrantDeferred Stock Units · Derivative | 6,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009208 · doc4.xml · derivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,805 Underlying: Common Stock · 6,109 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:43 UTC |
LUDWIG EDWARD JDirector
|
GrantCommon Stock | 2,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009206 · doc4.xml · nonDerivative · entry 2 LUDWIG EDWARD J · CIK 0001221783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,497 F2 · shares: Restricted stock granted in lieu of 50% of cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of $77,500, divided by the closing price of common stock on the date of grant. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:43 UTC |
LUDWIG EDWARD JDirector
|
GrantCommon Stock | 6,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009206 · doc4.xml · nonDerivative · entry 1 LUDWIG EDWARD J · CIK 0001221783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,938 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:29 UTC |
Zane Ellen MDirector
|
GrantCommon Stock | 6,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009203 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,053 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:29 UTC |
Sununu John EDirector
|
GrantCommon Stock | 6,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009202 · doc4.xml · nonDerivative · entry 1 Sununu John E · CIK 0001458974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,265 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:29 UTC |
ROUX DAVID JDirector
|
GrantCommon Stock | 6,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009201 · doc4.xml · nonDerivative · entry 1 ROUX DAVID J · CIK 0001234273 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,015 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:29 UTC |
JAMES DONNADirector
|
GrantCommon Stock | 6,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009200 · doc4.xml · nonDerivative · entry 1 JAMES DONNA · CIK 0001197735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,879 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:28 UTC |
Dockendorff Charles JDirector
|
GrantCommon Stock | 6,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009199 · doc4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,213 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:28 UTC |
Connors Nelda JDirector
|
GrantCommon Stock | 6,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009198 · doc4.xml · nonDerivative · entry 1 Connors Nelda J · CIK 0001478748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,442 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 10, 2018 Filed May 11, 2018 22:28 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
SaleCommon Stock | 7,500 | $30.06 | $225,412.50 |
DisclosureSEC source: 0001225208-18-009197 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,484 Read SEC document |
| May 07, 2018 Filed May 8, 2018 21:17 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 31,056 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-008924 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,056 Underlying: Common Stock · 31,056 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase 62,112 shares of common stock vesting in four annual increments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| May 07, 2018 Filed May 8, 2018 21:17 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
SaleCommon Stock | 31,056 | $30.00 | $931,680.00 |
DisclosureSEC source: 0001225208-18-008924 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,151 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 07, 2018 Filed May 8, 2018 21:17 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionCommon Stock | 31,056 | $7.16 | $222,360.96 |
DisclosureSEC source: 0001225208-18-008924 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 05, 2018 Filed Oct 31, 2018 20:10 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Exercise / conversionDeferred Stock Units · Derivative | 1,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015007 · doc4.xml · derivative · entry 4 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,526 Underlying: Common Stock · 1,526 shares Expires 2019-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on May 5, 2015. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on May 5, 2015. Read SEC document |
| May 05, 2018 Filed Oct 31, 2018 20:10 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Tax withholdingCommon Stock | 685 | $29.55 | $20,241.75 |
DisclosureSEC source: 0001225208-18-015007 · doc4.xml · nonDerivative · entry 2 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,003 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 05, 2018 Filed Oct 31, 2018 20:10 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Exercise / conversionCommon Stock | 1,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015007 · doc4.xml · nonDerivative · entry 1 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.